Novonesis (Novozymes) stock (DK0060336014): new China probiotics deal puts merger-made biosolutions leader in focus

Novonesis, created from the merger of Novozymes and Chr. Hansen, has signed a fresh strategic probiotics partnership in China, adding a new growth angle to the enzyme and biosolutions specialist as investors digest its post-merger position on Nasdaq Copenhagen.

Novonesis, the biosolutions group formed from the merger of Novozymes and Chr. Hansen, has entered a new strategic partnership with Chinese company UndoAge to accelerate the commercialization of its proprietary probiotic strains in China’s consumer health market, according to a press release distributed via PR Newswire on 06/10/2026.PR Newswire as of 06/10/2026 The deal highlights how the Denmark-based group is using its enlarged scale and portfolio after the Novozymes–Chr. Hansen merger to target high-growth regions in probiotics and consumer health.

The company is listed in Copenhagen and remains a notable constituent of the OMXC25 benchmark index, where Novonesis (Novozymes) B appears among the top Danish blue-chip names, according to index data from Nasdaq Copenhagen as of 05/28/2026.Nasdaq Copenhagen as of 05/28/2026 For US-based investors who access the stock via international trading platforms or through global funds, the new China partnership may be relevant as it touches on demand trends in probiotics and the group’s exposure to Asian consumer markets.

As of: 10.06.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Novonesis
• Sector/industry: Biotechnology, industrial enzymes and microbial solutions
• Headquarters/country: Denmark
• Core markets: Food and beverages, household care, agriculture, bioenergy and consumer health
• Key revenue drivers: Enzymes and microbial solutions for food, detergents, biofuels, agriculture and probiotics
• Home exchange/listing venue: Nasdaq Copenhagen (ticker: NSIS B)
• Trading currency: Danish krone (DKK)

Novonesis (Novozymes): core business model

Novonesis positions itself as a global biosolutions group built on the combined legacy of enzyme specialist Novozymes and microbial and probiotic expert Chr. Hansen, following the completion of their merger in 2024, as described in the company’s merger communications and investor materials published in early 2024.Novonesis investor relations as of 01/29/2024 The group focuses on enzymes, probiotics and microbial technologies designed to improve efficiency, quality and sustainability across industrial and consumer applications.

According to Novonesis investor presentations and its 2024 annual reporting, management highlights the breadth of its biosolutions portfolio across end markets such as food and beverages, household care, bioenergy, agriculture and consumer health.Novonesis stock information as of 03/18/2025 The combination of Novozymes and Chr. Hansen is intended to create a scaled platform with a deeper innovation pipeline and a wider customer base, with the goal of capturing growth in enzyme and microbial technologies as industries look for ways to reduce resource use and emissions.

In capital markets materials released in March 2025, Novonesis underlined anticipated cost synergies and cross-selling opportunities from the merger, noting that the integrated group aims to leverage shared R&D, global production and commercial infrastructure to strengthen its competitive position in biosolutions.Ad-hoc-news.de as of 04/25/2025 As a result, the company presents itself as a partner for customers seeking to optimize processes in areas such as detergents, food processing, biofuels and agriculture through tailored enzyme and microbial products.

From a business model perspective, Novonesis generates revenue largely by supplying highly specialized ingredients and solutions to B2B customers, often under long-term relationships where performance and reliability are critical. According to the company’s descriptions, enzyme and probiotic products are typically integrated into customers’ formulations, which can contribute to recurring demand if products perform as intended and switching costs remain meaningful.Novonesis investor relations as of 03/18/2025

Main revenue and product drivers for Novonesis (Novozymes)

Based on Novonesis disclosures, a significant share of the group’s revenue is linked to industrial enzymes used in household care, particularly laundry detergents and cleaning products, where enzymes help remove stains at lower temperatures and reduce the need for harsh chemicals.Novonesis investor relations as of 03/18/2025 This business depends on volumes and innovation cycles in global consumer goods markets as large customers look to differentiate their detergents through performance and sustainability claims.

Food and beverage applications represent another major driver, with enzymes and cultures used in baking, dairy, brewing and plant-based foods to improve texture, yield, shelf life and taste, according to information from the company’s segment descriptions in its 2024 annual report.Ad-hoc-news.de as of 03/18/2025 This area links Novonesis to global trends around convenience food, dairy alternatives and more resource-efficient production in food chains.

In bioenergy, Novonesis supplies enzyme solutions for the production of bioethanol and other biofuels, where enzymes help to break down raw materials such as corn or cellulosic biomass to improve yields. The company’s materials suggest that demand in this segment is influenced by energy markets, blending mandates and decarbonization policies, especially in the US and Europe.Novonesis investor relations as of 03/18/2025 Exposure to biofuels ties part of the revenue base to commodity cycles and regulatory developments.

The legacy Chr. Hansen businesses add probiotics and microbial solutions for human health, animal nutrition and agriculture. In human health, this includes strains and formulations used in dietary supplements and functional foods marketed for digestive and immune benefits, while in agriculture and animal feed the focus is on microbial products that support crop yields and animal health.Novonesis investor relations as of 01/29/2024 The new UndoAge partnership in China fits into this human health pillar, as it aims to scale Novonesis probiotics across Chinese consumer channels.

According to the 06/10/2026 press release, UndoAge and Novonesis plan to collaborate on advancing the commercialization of Novonesis’s proprietary probiotic strains and solutions within China’s probiotic industry, leveraging both companies’ expertise and presence in the market.Morningstar PR Newswire as of 06/10/2026 With China representing a significant and growing market for gut health and immunity-related products, the partnership could be relevant for Novonesis’s geographic diversification and its positioning in global consumer health.

Conclusion

Novonesis emerges from the Novozymes–Chr. Hansen merger as a scaled biosolutions company with exposure to enzymes, probiotics and microbial technologies across detergents, food, bioenergy and agriculture, according to its investor communications and 2024 reporting.Ad-hoc-news.de as of 04/25/2025 The new probiotics partnership with UndoAge in China adds another angle to the group’s consumer health ambitions and highlights its strategy of using proprietary strains in high-growth markets. For US-focused investors who follow global industrial and biotech names, Novonesis offers a case study in post-merger integration, index-level visibility on Nasdaq Copenhagen and direct exposure to structural themes like sustainable industrial processes and microbiome-based solutions, but the stock’s appeal ultimately depends on individual views regarding execution, regulatory environments and currency and market risks.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.